CA2438326A1 - Compositions and methods for enhancing drug delivery across and into epithelial tissues - Google Patents

Compositions and methods for enhancing drug delivery across and into epithelial tissues Download PDF

Info

Publication number
CA2438326A1
CA2438326A1 CA002438326A CA2438326A CA2438326A1 CA 2438326 A1 CA2438326 A1 CA 2438326A1 CA 002438326 A CA002438326 A CA 002438326A CA 2438326 A CA2438326 A CA 2438326A CA 2438326 A1 CA2438326 A1 CA 2438326A1
Authority
CA
Canada
Prior art keywords
delivery
conjugate
enhancing
arginine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438326A
Other languages
English (en)
French (fr)
Inventor
Jonathan B. Rothbard
Paul A. Wender
P. Leo Mcgrane
Lalitha V. S. Sista
Thorsten A. Kirschberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438326A1 publication Critical patent/CA2438326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA002438326A 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into epithelial tissues Abandoned CA2438326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/792,480 2001-02-23
US09/792,480 US6669951B2 (en) 1999-08-24 2001-02-23 Compositions and methods for enhancing drug delivery across and into epithelial tissues
PCT/US2002/005829 WO2002069930A1 (en) 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into epithelial tissues

Publications (1)

Publication Number Publication Date
CA2438326A1 true CA2438326A1 (en) 2002-09-12

Family

ID=25157022

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002438326A Abandoned CA2438326A1 (en) 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA002438784A Abandoned CA2438784A1 (en) 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into ocular tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002438784A Abandoned CA2438784A1 (en) 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into ocular tissues

Country Status (6)

Country Link
US (5) US6669951B2 (enExample)
EP (2) EP1367995A4 (enExample)
JP (2) JP2004533414A (enExample)
CA (2) CA2438326A1 (enExample)
MX (2) MXPA03007590A (enExample)
WO (2) WO2002069930A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US8623833B2 (en) 1999-08-24 2014-01-07 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
DE69930509T2 (de) * 1998-07-08 2006-11-30 Kirin-Amgen Inc., Wilmington Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8722668B2 (en) 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2797652C (en) * 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU1482102A (en) * 2000-11-14 2002-05-27 Tocovite Pty Ltd Complexes of phosphate derivatives
WO2002065986A2 (en) * 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
MXPA04000654A (es) 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
MXPA04005611A (es) * 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002359855B2 (en) 2001-12-21 2008-08-21 David S. Soane Use of oligomers and polymers for drug solublization, stabilization, and delivery
FR2836474B1 (fr) * 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
WO2003090604A2 (en) * 2002-04-24 2003-11-06 University Of Florida Method of endovascular brain mapping
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004017904A2 (en) * 2002-08-23 2004-03-04 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
US7458982B2 (en) * 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
JP2006524232A (ja) * 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
EP2351844B1 (en) * 2003-04-29 2014-06-11 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
EP1668145A4 (en) * 2003-08-07 2010-03-10 Avi Biopharma Inc SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050203041A1 (en) * 2003-09-23 2005-09-15 Mourich Dan V. Antisense compound and method for selectively killing activated T cells
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
DE10355559A1 (de) * 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
PT1729821E (pt) 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE602005025979D1 (de) * 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
EP1734991A4 (en) 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
DK1768657T3 (da) 2004-06-23 2008-12-01 Sirion Therapeutics Inc Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
EP2269650A3 (en) * 2004-08-03 2012-05-16 Vital Health Sciences Pty Ltd. Carrier for enteral administration
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US7603097B2 (en) 2004-12-30 2009-10-13 Valeo Radar Systems, Inc. Vehicle radar sensor assembly
AU2006213686A1 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
US8022179B2 (en) 2005-03-03 2011-09-20 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
CA2611831C (en) 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030576A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1924292A2 (en) * 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US7745392B2 (en) 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038171A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
CA2625918A1 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7740880B2 (en) 2006-03-03 2010-06-22 University Of Utah Research Foundation Polymeric carrier for delivery of small interfering RNA
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
BRPI0714762A2 (pt) * 2006-09-27 2014-12-23 Paolo Botti Meios e métodos de aumento de entrega para sistemas biológicos
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
US8772471B2 (en) * 2007-01-26 2014-07-08 Industry-University Cooperation Foundation Hanyang University Targeted delivery of siRNA
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
JP5864100B2 (ja) * 2007-06-29 2016-02-17 サレプタ セラピューティクス インコーポレイテッド 組織特異的ペプチドコンジュゲートおよび方法
AU2015200600B2 (en) * 2007-06-29 2017-04-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2178549B1 (en) 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20110160146A1 (en) * 2008-02-07 2011-06-30 National Institute of Health (NIH) Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance
EP2123262A1 (en) 2008-05-20 2009-11-25 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR20160083953A (ko) * 2008-09-23 2016-07-12 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
WO2010080554A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
TWI568447B (zh) 2009-05-08 2017-02-01 上海泰飛爾生化技術有限公司 具有快速透皮速度的多肽及多肽相關化合物的前藥組合物
WO2010141845A2 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011060320A1 (en) 2009-11-13 2011-05-19 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
AU2010321784B2 (en) * 2009-11-23 2014-04-24 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6336902B2 (ja) * 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104540504A (zh) 2012-01-18 2015-04-22 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
WO2013162729A1 (en) 2012-04-24 2013-10-31 The Board Of Trustees Of The Leland Stanford Junior University Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
US9782491B2 (en) 2012-06-04 2017-10-10 Indiana University Research And Technology Corporation Peptide conjugates for treating pain
US9089536B2 (en) 2012-06-06 2015-07-28 Brian J. Smith Ophthalmic solution for absorbing ultraviolet radiation and method for absorbing ultraviolet radiation
HK1212618A1 (zh) * 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
MX2015016588A (es) * 2013-06-11 2016-07-26 Portage Pharmaceuticals Ltd Estructura, fabricacion y usos de los peptidos permeables a las celulas, derivados de humanos, conjugados con los peptidos de carga especificos, biologicamente activos.
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
JP2016538327A (ja) 2013-09-24 2016-12-08 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用
PL3149025T3 (pl) 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3185880B1 (en) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
WO2018022930A1 (en) * 2016-07-27 2018-02-01 The Board Of Trustees Of The Leland Stanford Junior University Immolative cell-penetrating complexes for nucleic acid delivery
MD3554553T2 (ro) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
KR102093209B1 (ko) * 2017-05-11 2020-03-25 (주)케어젠 이소트레티노인과 펩타이드의 결합체
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3755351A4 (en) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY
JP2021107327A (ja) * 2018-04-09 2021-07-29 国立研究開発法人産業技術総合研究所 生理活性を持つ中分子の薬物動態を改善する方法、薬物動態の改善を利用した中分子ライブラリの製造法
EP3787671A4 (en) 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
SI3678705T1 (sl) 2018-09-14 2023-10-30 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Konjugati montelukasta in peptidov
CN109010798A (zh) * 2018-09-17 2018-12-18 中山大学中山眼科中心 一种多肽的新用途
WO2020117429A1 (en) * 2018-12-04 2020-06-11 Purdue Research Foundation Novel antibacterial cell-penetrating peptides
US20210346506A1 (en) * 2020-05-07 2021-11-11 Guibai Liang Prodrug of itraconazole and uses thereof
WO2024100552A1 (en) * 2022-11-08 2024-05-16 Alcon Inc. Prodrugs and compositions for ophthalmology applications

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE744988C (de) 1941-02-01 1944-02-22 Wilhelm Ulrich O Handschraem- und Schlitzsaege
GB744988A (en) 1952-01-31 1956-02-15 Allen & Hanburys Ltd Improvements in preparations of insulin
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4847240A (en) 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2967069D1 (en) 1978-01-16 1984-08-02 Univ Boston Effecting cellular uptake of molecules
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4880911A (en) 1982-03-19 1989-11-14 G. D. Searle & Co. Fused polypeptides and methods for their detection
JPH0236570B2 (ja) 1985-05-30 1990-08-17 Toko Yakuhin Kogyo Kk Shoenchintsunankozai
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5162505A (en) 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5028707A (en) 1989-11-20 1991-07-02 Board Of Regents, University Of Texas 4-hydroxyquinaldic acid derivatives
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DK0506884T3 (da) 1989-12-21 1996-11-04 Whitehead Biomedical Inst Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5646120A (en) 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5831001A (en) 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
ES2095959T3 (es) 1990-10-24 1997-03-01 Allelix Biopharma Inhibidores de la replicacion del virus vih a base de peptidos.
US5633230A (en) 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
JPH07500820A (ja) 1991-09-05 1995-01-26 ユニバーシティ オブ コネティカット ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達
DE69320469D1 (de) 1992-04-23 1998-09-24 Allelix Biopharma Behandlung von herpesvirus infektion
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994014464A1 (en) 1992-12-22 1994-07-07 Allelix Biopharmaceuticals Inc. Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide
WO1995011038A1 (en) 1993-10-22 1995-04-27 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
AU4690596A (en) 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
JP2000509394A (ja) 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
JPH10204000A (ja) 1997-01-22 1998-08-04 Nof Corp 経皮吸収促進剤
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
CA2797652C (en) 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
WO2002065986A2 (en) * 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
US9810571B1 (en) 2016-12-15 2017-11-07 Chung-Hsiu Su Hand truck with a loading weighing mechanism

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US8278264B2 (en) 1999-08-24 2012-10-02 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US8623833B2 (en) 1999-08-24 2014-01-07 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US8729010B2 (en) 1999-08-24 2014-05-20 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues

Also Published As

Publication number Publication date
MXPA03007591A (es) 2003-12-04
US20070173436A1 (en) 2007-07-26
US20020127198A1 (en) 2002-09-12
US8623833B2 (en) 2014-01-07
EP1367995A4 (en) 2007-08-01
EP1367995A1 (en) 2003-12-10
US20140213532A1 (en) 2014-07-31
CA2438784A1 (en) 2002-09-06
EP1372626A4 (en) 2007-08-01
MXPA03007590A (es) 2003-12-04
JP2004533414A (ja) 2004-11-04
EP1372626A1 (en) 2004-01-02
JP2004530657A (ja) 2004-10-07
US20110206610A1 (en) 2011-08-25
WO2002069930A1 (en) 2002-09-12
US20040186045A1 (en) 2004-09-23
US6669951B2 (en) 2003-12-30
WO2002067917A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
US6669951B2 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
US6759387B2 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US8729010B2 (en) Compositions and methods for enhancing drug delivery across and into ocular tissues
CA2437983C (en) Transporters comprising spaced arginine moieties
US20020009491A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
AU2002306500A1 (en) Transporters comprising spaced arginine moieties
AU2002303102A1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
HK1152869A (en) Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
AU2002245529A1 (en) Compositions and methods for enhancing drug delivery across and into ocular tissues

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued